Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Share :
Published: 25 Apr 2018
Views: 5291
Rating:
Save
Prof Alex Eggermont - Paris-Sud University, Paris, France

Prof Eggermont presents results at AACR 2018 from KEYNOTE-054, assessing disease recurrence rates in melanoma patients treated with pembrolizumab.

For more on this research, watch his interview with ecancer here.